BBIO
NASDAQ · Biotechnology
Bridgebio Pharma Inc
$74.29
+0.02 (+0.03%)
Financial Highlights (FY 2026)
Revenue
512.09M
Net Income
-739,405,176
Gross Margin
95.8%
Profit Margin
-144.4%
Rev Growth
+86.3%
D/E Ratio
8.27
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 95.8% | 95.8% | 62.1% | 62.1% |
| Operating Margin | -108.5% | -97.6% | -18.7% | -16.8% |
| Profit Margin | -144.4% | -137.2% | -18.6% | -18.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 512.09M | 274.88M | 2.34B | 2.57B |
| Gross Profit | 490.69M | 263.39M | 1.46B | 1.60B |
| Operating Income | -555,417,420 | -268,317,594 | -437,527,234 | -431,783,995 |
| Net Income | -739,405,176 | -357,200,568 | -436,239,166 | -483,541,824 |
| Gross Margin | 95.8% | 95.8% | 62.1% | 62.1% |
| Operating Margin | -108.5% | -97.6% | -18.7% | -16.8% |
| Profit Margin | -144.4% | -137.2% | -18.6% | -18.8% |
| Rev Growth | +86.3% | +86.3% | -0.2% | +8.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 6.47B | 6.47B | 6.47B | 5.73B |
| Total Equity | 782.53M | 782.53M | 7.68B | 7.94B |
| D/E Ratio | 8.27 | 8.27 | 0.84 | 0.72 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -549,894,750 | -280,407,950 | -548,703,476 | -540,979,015 |
| Free Cash Flow | — | — | -421,297,535 | -367,960,452 |